LOGIN  |  REGISTER
Terns Pharmaceuticals

908 Devices to Participate in Upcoming Investor Conferences

February 22, 2024 | Last Trade: US$6.70 0.08 -1.18

BOSTON / Feb 22, 2024 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences.

  • Cowen 44th Annual Healthcare Conference, Boston, MA
    Fireside chat on Wednesday, March 6th at 9:50 a.m. Eastern Time / 6:50 a.m. Pacific Time
  • KeyBanc Life Sciences & MedTech Forum (Virtual)
    Fireside chat on Wednesday, March 20th at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time

Interested parties may access a live and archived webcast of these sessions on the “Investors” section of the company website at: www.908devices.com.

About 908 Devices

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.

Chimerix

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page